Prognostic Value of HPV E6/E7 mRNA Assay in Women with Negative Colposcopy or CIN1 Histology Result: A Follow-Up Study

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Giorgi Rossi, Paolo ^a,f   Benevolo, Maria ^b   Vocaturo, Amina ^b   Caraceni, Donatella ^c   Ciccocioppo, Lucia ^c   Frega, Antonio ^d   Terrenato, Irene ^b   Zappacosta, Roberta ^e   French, Deborah ^d   Rosini, Sandra ^e  

^a Agency for Public Health Lazio Sanità   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c Renzetti Hospital   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

^f PATHOLOGY UNIT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; COLPOSCOPY; CONTROLLED STUDY; DIAGNOSTIC KIT; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE IDENTIFICATION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL TIME; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERUS BIOPSY; VIRUS ONCOGENE; VIRUS ONCOGENE E6; VIRUS ONCOGENE E7;

ADOLESCENT; ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, VIRAL; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PROGNOSIS; RNA, MESSENGER; YOUNG ADULT;

EID: 84874551784     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057600     Document Type: Article

References (50)

1. IARC (2005) IARC Handbooks of Cancer Prevention. Vol. 10. Cervix Cancer Screening. IARC, Lion.
2. Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J, (2006) Chapter 10: New dimensions in cervical cancer screening. Vaccine 24 Suppl 3: S3/90-7.
3. Giorgi Rossi P, Ricciardi A, Cohet C, Palazzo F, Furnari G, et al. (2009) Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy. BMC Public Health 9: 71.
4. The NHS Information Centre, Public Health Indicators and Population Statistics Team Cervical Screening Programme England (2010) Available: http://www.ic.nhs.uk/webfiles/publications/008_Screening/cervscreen0910/2009_10_Cervical_Bulletin_Final_Report_AI_v1F.pdf.Accessed 2011 Jul 31.
5. Ronco G, Giubilato P, Naldoni C, Zorzi M, Anghinoni E, et al. (2010) Extension of organised cervical cancer screening programmes in Italy and their process indicators: 2008 activity. Epidemiol Prev 34(Suppl 4): 35-51.
6. Anttila A, Kotaniemi-Talonen L, Leinonen M, Hakama M, Laurila P, et al. (2010) Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ Apr 24 340: c1804 doi:10.1136/bmj.c1804.
7. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, et al. (2007) Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370: 1764-1772.
8. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, et al. (2009) HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 10: 672-682. Erratum in: Lancet Oncol Aug 10(8): 748.
9. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, et al. (2007) Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357: 1589-1597.
10. Ronco G, Giorgi Rossi P, Carozzi F, Confortini M, Dalla Palma P, et al. (2008) Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 100: 492-501.
11. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, et al. (2008) European guidelines for quality assurance in cervical cancer screening. 2nd edition. Luxembourg: Office for Official Publications of the European Communities.
12. Castle PE, Rodríguez AC, Burk RD, Herrero R, Hildesheim A, et al. (2009) Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. Int J Cancer 125: 1649-1656.
13. Massad LS, Jeronimo J, Katki HA, Schiffman M, National Institutes of Health/American Society for Colposcopy and Cervical Pathology Research Group (2009) The accuracy of colposcopic grading for detection of high-grade cervical intraepithelial neoplasia. J Low Genit Tract Dis 13: 137-144.
14. Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, Richards-Kortum R, (1998) Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet. Gynecol 91: 626-631.
15. Pretorius RG, Belinson JL, Burchette RJ, Hu S, Zhang X, et al. (2011) Regardless of skill, performing more biopsies increases the sensitivity of colposcopy. J Low Genit Tract Dis 15: 180-188.
16. Zuchna C, Hager M, Tringler B, Georgoulopoulos A, Ciresa-Koenig A, et al. (2010) Diagnostic accuracy of guided cervical biopsies: a prospective multicenter study comparing the histopathology of simultaneous biopsy and cone specimen. Am J Obstet Gynecol 203: 321.e1-6.
17. Stoler MH, Vichnin MD, Ferenczy A, Ferris DG, Perez G, et al. (2011) The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer 128: 1354-1362.
18. Castle PE, Gravitt PE, Wentzensen N, Schiffman M, (2012) A descriptive analysis of prevalent vs incident cervical intraepithelial neoplasia grade 3 following minor cytologic abnormalities. Am J Clin Pathol 138: 241-246.
19. Kjaer SK, Frederiksen K, Munk C, Iftner T, (2010) Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 102: 1478-1488.
20. Castle PE, Gage JC, Wheeler CM, Schiffman M, (2011) The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy. Obstet Gynecol 118: 1222-1229.
21. Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, et al. (2009) ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 13: 1-150, iii-iv.
22. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J, et al. (2009) Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 45(Suppl 1): S55-61.
23. von Knebel Doeberitz M, (2002) New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 38: 2229-2242.
24. Cuschieri K, Wentzensen N, (2008) Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev 17: 2536-2545.
25. Benevolo M, Terrenato I, Mottolese M, Marandino F, Carosi M, et al. (2011) Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients. Cancer Causes Control 22: 869-875.
26. Benevolo M, Vocaturo A, Caraceni D, French D, Rosini S, et al. (2011) Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol 49: 2643-2650.
27. Castle PE, Dockter J, Giachetti C, Garcia FA, McCormick MK, et al. (2007) A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res 13: 2599-2605.
28. Lie AK, Kristensen G, (2008) Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma. Expert Rev Mol Diagn 8: 405-415.
29. Donà MG, Vocaturo A, Giuliani M, Ronchetti L, Rollo F, et al. (2012) p16/Ki-67 dual staining in cervico-vaginal cytology: Correlation with histology, Human Papillomavirus detection and genotyping in women undergoing colposcopy.Gynecol Oncol. 126: 198-202.
30. Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, Gillio-Tos A, et al. (2008) Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 9: 937-945.
31. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, et al. (2001) Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 92: 276-284.
32. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, et al. (2008) Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol Biomarkers Prev 17: 3033-3042.
33. Halfon P, Benmoura D, Agostini A, Khiri H, Martineau A, et al. (2010) Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ HPV assay. J Clin Virol 47: 177-181.
34. Lie AK, Risberg B, Borge B, Sandstad B, Delabie J, et al. (2005) DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol Oncol 97: 908-915.
35. Molden T, Nygard JF, Kraus I, Karlsen F, Nygard M, et al. (2005) Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 114: 973-976.
36. Ratnam S, Coutlee F, Fontaine D, Bentley J, Escott N, et al. (2010) Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer. J Clin Microbiol 48: 2779-2785.
37. Rosini S, Zappacosta R, Di Bonaventura G, Caraceni D, Pilla D, et al. (2007) Management and triage of women with human papillomavirus infection in follow-up for low-grade cervical disease: association of HPV-DNA and RNA-based methods. Int J Immunopathol Pharmacol 20: 341-347.
38. Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, et al. (2013) The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: A meta-analysis of the diagnostic accuracy. Int J Cancer 132: 101-108.
39. Sørbye SW, Fismen S, Gutteberg T, Mortensen ES, (2010) Triage of women with minor cervical lesions: data suggesting a "test and treat" approach for HPV E6/E7 mRNA testing. PLoS One 5: e12724.
40. Szarewski A, Mesher D, Cadman L, Austin J, Ashdown-Barr L, et al. (2012) Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol 50: 1867-1873.
41. Koliopoulos G, Chrelias C, Pappas A, Makridima S, Kountouris E, et al. (2012) The diagnostic accuracy of two methods for E6&7 mRNA detection in women with minor cytological abnormalities. Acta Obstet Gynecol Scand 91: 794-801.
42. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, et al. (2002) Forum Group Members; Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287: 2114-2119.
43. Moyer VA, on behalf of the U.S. Preventive Services Task Force (2012) Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2012 Mar 14.
44. Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, et al. (2012) Health Technology Assessment Report: HPV DNA based primary screening for cervical cancer precursors. Epidemiol Prev 36(3-4Suppl 1): 1-72.
45. Rijkaart DC, Heideman DA, Coupe VM, Brink AA, Verheijen RH, et al. (2012) High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytology. J Clin Microbiol 50: 2390-2396.
46. Castle PE, Katki HA, (2010) Benefits and risks of HPV testing in cervical cancer screening. Lancet Oncol 11: 214-215.
47. Sørbye SW, Arbyn M, Fismen S, Gutteberg TJ, Mortensen ES (2011) HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy. PLoS One 6: e26022, Epub Oct 6.
48. Dillner J, Rebolj M, Birembaut P, Petry K-U, Szarewski A, et al. (2008) Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337: a1754.
49. Hariri J, Øster A, (2007) The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix. Int J Gynecol Pathol 26: 223-228.
50. Ronco G, Giorgi Rossi P, Carozzi F, Confortini M, Dalla Palma P, et al. (2010) Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 11: 249-257.